Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2876103rdf:typepubmed:Citationlld:pubmed
pubmed-article:2876103lifeskim:mentionsumls-concept:C0034798lld:lifeskim
pubmed-article:2876103lifeskim:mentionsumls-concept:C0002522lld:lifeskim
pubmed-article:2876103lifeskim:mentionsumls-concept:C0026669lld:lifeskim
pubmed-article:2876103lifeskim:mentionsumls-concept:C0733755lld:lifeskim
pubmed-article:2876103lifeskim:mentionsumls-concept:C1709915lld:lifeskim
pubmed-article:2876103lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:2876103lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:2876103lifeskim:mentionsumls-concept:C1707271lld:lifeskim
pubmed-article:2876103pubmed:issue10lld:pubmed
pubmed-article:2876103pubmed:dateCreated1986-11-19lld:pubmed
pubmed-article:2876103pubmed:abstractTextThe synthesis of several analogues of L-prolyl-L-leucylglycinamide (PLG) was carried out in which the glycinamide residue was replaced with the following cyclic amino acid residues: L- and D-prolinamide, (+)- and (-)-thiazolidine-2-carboxamide, L- and D-3,4-dehydroprolinamide, L-azetidine-2-carboxamide, L-piperidine-2-carboxamide, and L-thiazolidine-4-carboxamide to give PLG analogues 2-10, respectively. The ability of these analogues to enhance the binding of the dopamine agonist ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) to dopamine receptors was determined by using bovine brain tissue. All of the PLG analogues synthesized in this study enhanced the binding of ADTN to central dopamine receptors. The percent enhancement of ADTN binding produced by analogues 2,3, and 7-10 at various concentrations was comparable to the percent enhancement produced by PLG. The PLG analogues Pro-Leu-(+)-thiazolidine-2-carboxamide (4), Pro-Leu-(-)-thiazolidine-2-carboxamide (5), and Pro-Leu-L-3,4-dehydroprolinamide (6), however, produced significantly greater enhancement (2-3-fold) in ADTN binding than did PLG.lld:pubmed
pubmed-article:2876103pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:languageenglld:pubmed
pubmed-article:2876103pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:citationSubsetIMlld:pubmed
pubmed-article:2876103pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2876103pubmed:statusMEDLINElld:pubmed
pubmed-article:2876103pubmed:monthOctlld:pubmed
pubmed-article:2876103pubmed:issn0022-2623lld:pubmed
pubmed-article:2876103pubmed:authorpubmed-author:JohnsonR LRLlld:pubmed
pubmed-article:2876103pubmed:authorpubmed-author:MishraR KRKlld:pubmed
pubmed-article:2876103pubmed:authorpubmed-author:RajakumarGGlld:pubmed
pubmed-article:2876103pubmed:issnTypePrintlld:pubmed
pubmed-article:2876103pubmed:volume29lld:pubmed
pubmed-article:2876103pubmed:ownerNLMlld:pubmed
pubmed-article:2876103pubmed:authorsCompleteYlld:pubmed
pubmed-article:2876103pubmed:pagination2100-4lld:pubmed
pubmed-article:2876103pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:meshHeadingpubmed-meshheading:2876103-...lld:pubmed
pubmed-article:2876103pubmed:year1986lld:pubmed
pubmed-article:2876103pubmed:articleTitleDopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position.lld:pubmed
pubmed-article:2876103pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2876103pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:2876103pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:2876103lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2876103lld:pubmed